Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Accumulated Expenses (2023 - 2025)

Mangoceuticals' Accumulated Expenses history spans 3 years, with the latest figure at $4460.0 for Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 20.07% year-over-year to $4460.0; the TTM value through Sep 2025 reached $4460.0, down 20.07%, while the annual FY2023 figure was $6595.0, N/A changed from the prior year.
  • Accumulated Expenses for Q3 2025 was $4460.0 at Mangoceuticals, up from $2973.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $8203.0 in Q1 2024 and bottomed at $2973.0 in Q2 2025.
  • The 3-year median for Accumulated Expenses is $5580.0 (2024), against an average of $5694.1.
  • The largest annual shift saw Accumulated Expenses skyrocketed 85.42% in 2024 before it tumbled 36.57% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $6595.0 in 2023, then fell by 15.39% to $5580.0 in 2024, then decreased by 20.07% to $4460.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Accumulated Expenses are $4460.0 (Q3 2025), $2973.0 (Q2 2025), and $5580.0 (Q3 2024).